This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believe",
"continue", "estimate", "expect", "intends", "may", "should", "will" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. The Company does not accept any obligation or undertaking to update,
review or revise any forward-looking statement contained in this announcement
whether as a result of new information, future developments or otherwise,
other than as may be required by law.
Bergen, Norway, November 1st, 2023: Today, Lifecare AS (LIFE) (the "Company"),
a clinical stage medical sensor company developing the next generation
Continuous Glucose Monitor (CGM), publishes a new valuation report of
Lifecare's CGM-technology.
The report is enclosed and available on the Company's website
lifecare.no/news/
Commissioned by Lifecare, the life science technology valuation-company Xplico
has carried out an in-depth value review of the Sencell technology. For the
evaluation, Xplico has obtained information from Lifecare, but in their
disclaimer they also emphasized how they have evaluated the information
provided to them through broad inquiry, analysis and review.
In this valuation of Lifecare's technology, Xplico has taken into
consideration various factors like development and market assumptions,
comparable CGM technologies and concluded a valuation outcome.
- The valuation is comprehensive and provides an assessment of net present
values of Lifecares technology. The evaluation also provides, among other
things, assessments regarding the probability of success in the markets we
have targeted. In addition, the report shows market share and anticipated
annual treatment price at launch. For the very first time, the spin-off
venture towards the veterinary market has also received a separate review. The
valuations of the technology in the markets for both humans and pets confirm
the possibilities of Lifecare's technology, announces CEO Joacim Holter at
Lifecare.
Xplico is a market leader in life science valuation. Half of their client base
is in North America, while the rest of the assignments come from customers in
Europe and Asia. Annually, Xplico carries out a broad range of company
valuations in addition to offering standardized valuation tools.
Contacts
For further information, please contact:
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40
Asle Wingsternes, Head of Communications & Public Affairs,
asle.wingsternes@lifecare.no, +47 41 61 42 52
This information is information that Lifecare AS is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact persons set out above, at
2023-11-01 08:00 CET.